Emergent Financial Statements From 2010 to 2022

EBS
 Stock
  

USD 32.65  2.12  6.94%   

Emergent Biosolutions financial statements provide useful quarterly and yearly information to potential Emergent Biosolutions investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Emergent Biosolutions financial statements helps investors assess Emergent Biosolutions' valuation, profitability, and current liquidity needs.
There are over one hundred ten available fundamental signals for Emergent Biosolutions, which can be analyzed over time and compared to other ratios. Please make sure to verify Emergent Biosolutions' prevailing fundamental performance against the performance between 2010 and 2022 to make sure the trends are evolving in the right direction.
Emergent Biosolutions Earnings Before Interest Taxes and Depreciation Amortization EBITDA are relatively stable at the moment as compared to the past year. Emergent Biosolutions reported last year Earnings Before Interest Taxes and Depreciation Amortization EBITDA of 469.6 Million. As of 06/30/2022, Earnings before Tax is likely to grow to about 339.2 M, while Net Income Per Employee is likely to drop slightly above 83 K.
  
Refresh
Check Emergent Biosolutions financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Emergent main balance sheet or income statement drivers, such as Direct Expenses of 817.3 M, Consolidated Income of 249.1 M or Cost of Revenue of 817.3 M, as well as many exotic indicators such as Interest Coverage of 12.72, Long Term Debt to Equity of 0.42 or Calculated Tax Rate of 32.86. Emergent financial statements analysis is a perfect complement when working with Emergent Biosolutions Valuation or Volatility modules. It can also supplement various Emergent Biosolutions Technical models. Continue to the analysis of Emergent Biosolutions Correlation against competitors.

Emergent Biosolutions Revenues

1.93 Billion

Share

Emergent Biosolutions Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.2 BB1.5 B
Increasing
Slightly volatile
Cash and Equivalents621.6 M576.1 M290.5 M
Increasing
Slightly volatile
Investments1.8 M1.8 M1.9 M
Decreasing
Slightly volatile
Investments Current1.8 M1.8 M1.9 M
Decreasing
Slightly volatile
Deferred Revenue37.8 M35.1 M18.1 M
Increasing
Slightly volatile
Property Plant and Equipment Net665.2 M800.1 M423.9 M
Increasing
Slightly volatile
Inventory378.5 M350.8 M143.6 M
Increasing
Slightly volatile
Tax Assets16.7 M19.8 M17.4 M
Increasing
Very volatile
Trade and Non Trade Receivables235.3 M274.7 M156.5 M
Increasing
Slightly volatile
Trade and Non Trade Payables104.4 M128.9 M64.6 M
Increasing
Slightly volatile
Goodwill and Intangible Assets660.3 M829.5 M378.3 M
Increasing
Slightly volatile
Total Liabilities1.4 B1.3 B654.6 M
Increasing
Slightly volatile
Shareholders Equity1.7 B1.6 B873 M
Increasing
Slightly volatile
Accumulated Retained Earnings DeficitB957.8 M431.1 M
Increasing
Slightly volatile
Current Assets1.4 B1.3 B626.8 M
Increasing
Slightly volatile
Assets Non Current1.4 B1.7 B869.9 M
Increasing
Slightly volatile
Current Liabilities403.3 M373.8 M172.5 M
Increasing
Slightly volatile
Liabilities Non Current779.8 M966.2 M461.1 M
Increasing
Slightly volatile
Tax Liabilities15.5 M14.4 M9.2 M
Increasing
Slightly volatile
Total Debt668.2 M841 M385.6 M
Increasing
Slightly volatile
Debt Current26.4 M31.6 M16.9 M
Increasing
Slightly volatile
Debt Non Current645.3 M809.4 M374.4 M
Increasing
Slightly volatile
Shareholders Equity USD1.3 B1.6 B845 M
Increasing
Slightly volatile
Cash and Equivalents USD460.3 M576.3 M276 M
Increasing
Slightly volatile
Total Debt USD668.2 M841 M385.6 M
Increasing
Slightly volatile
Accounts Payable139.1 M128.9 M66.7 M
Increasing
Slightly volatile
Receivables296.4 M274.7 M159 M
Increasing
Slightly volatile
Inventories378.5 M350.8 M144.7 M
Increasing
Slightly volatile

Emergent Biosolutions Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues1.9 B1.8 B796 M
Increasing
Slightly volatile
Cost of Revenue817.3 M757.5 M274.7 M
Increasing
Slightly volatile
Selling General and Administrative Expense282.4 M348.4 M172.2 M
Increasing
Slightly volatile
Research and Development Expense209 M234 M151.1 M
Increasing
Slightly volatile
Operating Expenses558.3 M682.6 M349.1 M
Increasing
Slightly volatile
Interest Expense27.4 M34.5 M13.7 M
Increasing
Slightly volatile
Income Tax Expense90.1 M83.5 M40.2 M
Increasing
Slightly volatile
Net Loss Income from Discontinued Operations13 M9.6 M14.8 M
Decreasing
Slightly volatile
Consolidated Income249.1 M230.9 M93.6 M
Increasing
Slightly volatile
Net Income249.1 M230.9 M97.4 M
Increasing
Slightly volatile
Net Income Common Stock249.1 M230.9 M95.2 M
Increasing
Slightly volatile
Weighted Average Shares45.9 M53.5 M42.4 M
Increasing
Slightly volatile
Weighted Average Shares Diluted47.6 M54.1 M45.7 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT376.4 M348.9 M149.3 M
Increasing
Slightly volatile
Revenues USD1.9 B1.8 B788.9 M
Increasing
Slightly volatile
Net Income Common Stock USD249.1 M230.9 M95.2 M
Increasing
Slightly volatile
Earning Before Interest and Taxes USD376.4 M348.9 M149.3 M
Increasing
Slightly volatile
Gross Profit825.7 MB491.8 M
Increasing
Slightly volatile
Operating Income380.4 M352.6 M148.7 M
Increasing
Slightly volatile
Direct Expenses817.3 M757.5 M278.6 M
Increasing
Slightly volatile

Emergent Biosolutions Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals2.4 M2.3 M1.7 M
Increasing
Slightly volatile
Net Cash Flow from Financing(144.7 M)(141 M)54.7 M
Decreasing
Very volatile
Issuance Repayment of Debt Securities (36.8 M)(35.9 M)72.6 M
Increasing
Very volatile
Issuance Purchase of Equity Shares(92.5 M)(90.1 M)(4.8 M)
Decreasing
Slightly volatile
Net Cash Flow from Operations346.4 M321.1 M161.7 M
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (307.9 K)(300 K)(126.8 K)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(46.4 M)(45.2 M)25.8 M
Increasing
Stable
Share Based Compensation45.7 M42.4 M19.5 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion133.6 M123.8 M57.1 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share4.664.322.0579
Increasing
Slightly volatile
Earnings per Diluted Share4.614.271.9743
Increasing
Slightly volatile
Earnings per Basic Share USD4.664.321.9826
Increasing
Slightly volatile
Return on Average Equity12.2215.06210.3585
Increasing
Slightly volatile
Return on Average Assets6.837.90466.3822
Increasing
Very volatile
Return on Invested Capital0.160.1730.1335
Increasing
Slightly volatile
Gross Margin72.0757.745371.9846
Decreasing
Slightly volatile
Profit Margin11.5412.8811.3286
Increasing
Very volatile
EBITDA Margin23.4626.195123.0146
Increasing
Slightly volatile
Return on Sales0.210.1950.1771
Increasing
Slightly volatile
Asset Turnover0.630.61370.5512
Increasing
Very volatile
Enterprise Value over EBITDA6.045.88910.5464
Decreasing
Stable
Enterprise Value over EBIT8.218.015.3239
Increasing
Very volatile
Price to Earnings Ratio10.3310.06226.0515
Decreasing
Stable
Sales per Share36.1533.508416.9561
Increasing
Slightly volatile
Price to Sales Ratio1.331.2972.5318
Decreasing
Very volatile
Price to Book Value1.991.4442.0571
Increasing
Slightly volatile
Debt to Equity Ratio0.430.51950.3766
Increasing
Slightly volatile
Current Ratio4.123.40324.0389
Decreasing
Stable
Free Cash Flow per Share1.591.79631.5347
Increasing
Slightly volatile
Book Value per Share26.7130.26218.7159
Increasing
Slightly volatile
Tangible Assets Book Value per Share34.8839.80424.2109
Increasing
Slightly volatile
Total Assets Per Share62.2357.680332.4776
Increasing
Slightly volatile
Cash Flow Per Share6.756.25933.3998
Increasing
Slightly volatile
Return on Investment12.5214.747311.3943
Increasing
Stable
Operating Margin17.5819.668717.2088
Increasing
Stable
Calculated Tax Rate32.8626.558532.6244
Decreasing
Slightly volatile
Receivables Turnover5.847.09145.0631
Increasing
Stable
Inventory Turnover2.682.30312.5383
Decreasing
Slightly volatile
PPandE Turnover2.042.48261.7641
Increasing
Slightly volatile
Cash and Equivalents Turnover2.832.99432.9768
Increasing
Slightly volatile
Accounts Payable Turnover12.1913.529812.0537
Increasing
Slightly volatile
Accrued Expenses Turnover12.9313.186514.1428
Decreasing
Very volatile
Interest Coverage12.7210.220311.0306
Increasing
Stable
Long Term Debt to Equity0.420.50.365
Increasing
Slightly volatile
Quick Ratio2.962.25563.0549
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets34.8130.358232.7164
Decreasing
Slightly volatile
Revenue to Assets0.610.60580.512
Increasing
Stable

Emergent Biosolutions Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax339.2 M314.4 M135.4 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA506.7 M469.6 M201.6 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD510 M472.7 M206.4 M
Increasing
Slightly volatile
Market Capitalization2.3 B2.3 B1.8 B
Increasing
Slightly volatile
Enterprise Value2.6 B2.8 B1.9 B
Increasing
Slightly volatile
Invested Capital1.7 BBB
Increasing
Slightly volatile
Average Equity1.3 B1.6 B777 M
Increasing
Slightly volatile
Average Assets2.3 B2.9 B1.3 B
Increasing
Slightly volatile
Invested Capital Average1.6 BB956.2 M
Increasing
Slightly volatile
Tangible Asset Value1.7 B2.1 B1.1 B
Increasing
Slightly volatile
Free Cash Flow91.2 M96.1 M63.2 M
Increasing
Slightly volatile
Working Capital723.7 M898.3 M436.5 M
Increasing
Slightly volatile
Revenue Per Employee633.6 K742 K581.7 K
Increasing
Slightly volatile
Net Income Per Employee83 K95.6 K78.1 K
Increasing
Slightly volatile

Emergent Fundamental Market Drivers

Forward Price Earnings12.26
Short Percent Of Float10.54%
Average Daily Volume Last 10 Day641.41k
Shares Short Prior Month3.34M
Average Daily Volume In Three Month766.67k
Date Short Interest15th of June 2022
Fifty Day Average32.63
Two Hundred Day Average42.25

Emergent Upcoming Events

Upcoming Quarterly Report17th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End17th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Emergent Biosolutions Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Emergent Biosolutions income statement, its balance sheet, and the statement of cash flows. Emergent Biosolutions investors use historical funamental indicators, such as Emergent Biosolutions's revenue or net income, to determine how well the company is positioned to perform in the future. Although Emergent Biosolutions investors may use each financial statement separately, they are all related. The changes in Emergent Biosolutions's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Emergent Biosolutions's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Emergent Biosolutions Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Emergent Biosolutions. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue35.1 M37.8 M
Cost of Revenue757.5 M817.3 M
Revenues1.8 B1.9 B
Revenue to Assets 0.61  0.61 
Revenue Per Employee742 K633.6 K
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people.

Emergent Biosolutions Investors Sentiment

The influence of Emergent Biosolutions' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Emergent. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Emergent Biosolutions in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Emergent Biosolutions' short interest history, or implied volatility extrapolated from Emergent Biosolutions options trading.

Current Sentiment - EBS

Emergent Biosolutions Investor Sentiment

Greater number of Macroaxis users are currently bullish on Emergent Biosolutions. What is your opinion about investing in Emergent Biosolutions? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Emergent Biosolutions

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.

Emergent Biosolutions Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.
The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Emergent Biosolutions Correlation against competitors. Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Emergent Stock analysis

When running Emergent Biosolutions price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.022
Market Capitalization
1.6 B
Quarterly Revenue Growth YOY
-0.1
Return On Assets
0.0677
Return On Equity
0.1
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine Emergent Biosolutions value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.